



# **The deregulation of Fyn kinase in Alzheimer's Disease**

**Goce Taleski**

*A thesis submitted in fulfilment of the requirements for the degree  
of Doctor of Philosophy*

**School of Biomedical Sciences and Pharmacy**

**Faculty of Health and Medicine**

September 2020

*This research was supported by an Australian Government Research Training  
Program (RTP) Scholarship*

## STATEMENT OF ORIGINALITY

*I hereby certify that the work embodied in the thesis is my own work, conducted under normal supervision. The thesis contains no material which has been accepted, or is being examined, for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made. I give consent to the final version of my thesis being made available worldwide when deposited in the University's Digital Repository, subject to the provisions of the Copyright Act 1968 and any approved embargo.*

*Goce Taleski*

## ACKNOWLEDGEMENT OF AUTHORSHIP

*I hereby certify that the work embodied in this thesis contains published papers of which I am a joint author. I have included as part of the thesis a written declaration endorsed in writing by my supervisor, attesting to my contribution to the joint publications.*

*By signing below, I confirm that Goce Taleski contributed to the following publications entitled:*

- 1. Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice*
- 2. Methylenetetrahydrofolate reductase deficiency deregulates regional brain amyloid- $\beta$  protein precursor expression and phosphorylation levels*
- 3. The protein serine/threonine phosphatases PP2A, PP1 and calcineurin: A triple threat in the regulation of the neuronal cytoskeleton*
- 4. Protein Phosphatase 2A and Tau: an orchestrated 'Pas de Deux'*
- 5. Disturbances in PP2A methylation and one-carbon metabolism critically affect Fyn distribution and function (submitted)*

*Outlined below are the items that the candidate has contributed towards:*

- Conduction of experiments (1, 2 and 5)*
- Analysis of results (2 and 5)*
- Review of literature (3 and 4)*
- Prepared and organised the figures (2, 3 and 4)*

*A/Prof Estelle Sontag*

## **ACKNOWLEDGEMENTS**

First, and foremost, I would like to express my infinite gratitude to my incredible supervisors, Associate Professor Estelle Sontag and Dr. Jean-Marie Sontag for the continuous support and enrichment of my university journey. Thank you, Estelle and Jean-Marie, for taking me under your wings, sharing your valuable knowledge and introducing me to a whole new level of research. I could not have imagined having better mentors or a more interesting and worthwhile project to work on.

I would also like to acknowledge the other members of my research group, Dr. Alexander Hoffman and Diana Schuhmacher, for their assistance, support and co-operation, which significantly influenced my work.

Last but not least, I would like to thank my partner Yangchen, family and friends for their love and support throughout my university journey.

## LIST OF PUBLICATIONS

1. Sontag JM, Wasek B, **Taleski G**, Smith J, Arning E, Sontag E, Bottiglieri T, *Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice*. FRONT AGING NEUROSCI, 22;6 (2014)
2. Hoffman A, **Taleski G**, Qian H, Wasek B, Arning E, Bottiglieri T, Sontag JM, Sontag E. *Methylenetetrahydrofolate reductase deficiency deregulates regional brain amyloid- $\beta$  protein precursor expression and phosphorylation levels*. J ALZHEIMERS DIS, 64(1) (2018)
3. Hoffman A, **Taleski G**, Sontag, E, *The protein serine/threonine phosphatases PP2A, PP1 and calcineurin: A triple threat in the regulation of the neuronal cytoskeleton*. MOL CELL NEUROSCI, 84 (2017)
4. **Taleski G**, Sontag E, *Protein Phosphatase 2A and Tau: an orchestrated 'Pas de Deux'*. FEBS LETT, 592(7) (2018)
5. **Taleski G**, Schumacher D, Su H, Sontag JM, Sontag E. *Disturbances in PP2A methylation and one-carbon metabolism compromises Fyn distribution, neuritogenesis and APP regulation*. J BOL CHEM, 296(100237) (2020)

*See Appendix for Publications 1-5.*

## CONFERENCE ABSTRACTS

**Taleski G**, Hoffman A, Qian H, Wasek B, Arning E, Bottiglieri T, Sontag JM and Sontag E. *MTHFR deficiency and low dietary folate interact to promote the accumulation of phosphorylated amyloid protein precursor and tau*. The 38th Annual Scientific Meeting of the Australasian Neuroscience Society, Brisbane, Australia, December 2018. Poster presenter.

Bottiglieri T, Hoffman A, **Taleski G**, Qian H, Wasek B, Arning E, Sontag JM and Sontag E. *Methylenetetrahydrofolate reductase (MTHFR) deficiency deregulates regional brain amyloid- $\beta$  precursor protein and phosphorylation levels*. FASEB Conference on Folic Acid, Vitamin B12 and One-Carbon Metabolism, Nova Scotia, Canada, August 2018.

Sontag JM, Gomez RJ, Hoffman A, **Taleski G**, Mazalouskasb MD, Hanks SK, Frohner I, Ogris E, Wadzinski BE and Sontag E. *At the crossroads between Tyr and Ser/Thr signaling: A new paradigm in the regulation of PP2A by Src kinase*. The American Society for Biochemistry and Molecular Biology 2017 Annual Meeting/ Experimental Biology 2017, Chicago, USA April 2017. The FASEB Journal vol. 31 no. 1 Supplement 771.2, April 2017.

Sontag JM, Wasek B, **Taleski G**, Smith J, Arning E, Sontag E and Bottiglieri T. *Methylation of protein phosphatase 2A and phosphorylation of Tau protein in brain tissue from methylenetetrahydrofolate reductase deficient mice*. FASEB Conference on Folic Acid, Vitamin B12 and One-Carbon Metabolism, Steamboat Springs, Colorado, August 2014.

## ORAL PRESENTATIONS AT CONFERENCES

**Taleski G**, Hoffman A, Qian H, Wasek B, Arning E, Bottiglieri T, Sontag JM, Sontag E. (Newcastle, Australia, 3rd August 2019) “A novel metabolic intervention for Tauopathies” **Centre for Brain and Mental Health Research, Hunter Medical Research Institute, 2019.**

**Taleski G**, van Hummel A, Ittner L, Sontag JM, Sontag E. (Newcastle, Australia, 2nd August 2018) “MTHFR deficiency and low dietary folate interact to promote the accumulation of phosphorylated amyloid protein precursor and tau” **Centre for Brain and Mental Health Research, Hunter Medical Research Institute, 2018.**

## **LIST OF AWARDS**

**2018**

**Travel Grant**

*Hunter Medical Research Institute (HMRI)*

**2017**

**Higher Degree by Research Award for Best Confirmation**

*University of Newcastle*

**2016**

**Australian Government Research Training Program (RTP) Scholarship**

**Faculty of Health and Medicine Medal**

*University of Newcastle*



# TABLE OF CONTENTS

<i>STATEMENT OF ORIGINALITY</i> .....	<i>ii</i>
<i>ACKNOWLEDGEMENT OF AUTHORSHIP</i> .....	<i>iii</i>
<i>ACKNOWLEDGEMENTS</i> .....	<i>iv</i>
<i>LIST OF PUBLICATIONS</i> .....	<i>v</i>
<i>CONFERENCE ABSTRACTS</i> .....	<i>vi</i>
<i>ORAL PRESENTATIONS AT CONFERENCES</i> .....	<i>vii</i>
<i>LIST OF AWARDS</i> .....	<i>viii</i>
<i>LIST OF FIGURES</i> .....	<i>xiii</i>
<i>LIST OF TABLES</i> .....	<i>xv</i>
<i>LIST OF ABBREVIATIONS</i> .....	<i>xvi</i>
<i>ABSTRACT</i> .....	<i>xvii</i>
<i>Chapter 1 Introduction</i> .....	<i>1</i>
1.1 Alzheimer's Disease (AD) .....	1
1.2 AD symptomatic onset and clinical progression .....	1
1.3 Modifiable and genetic risk factors of AD .....	2
1.4 Neuropathological hallmarks of AD .....	2
1.5 Amyloid Precursor Protein (APP) and its aberrant processing in AD .....	4
1.6 Tau and its excessive phosphorylation in AD .....	7
1.7 Fyn, a major brain kinase implicated in AD .....	11
1.8 Methylated PP2A enzymes crucially regulate APP and Tau .....	17
1.9 The delicate balance between Fyn-Tau and PP2A-Tau interactions, and possibly, Fyn-PP2A interactions .....	18
1.10 Folate and homocysteine metabolism and its clinical relevance in AD .....	19
1.11 The failure of numerous clinical interventions for AD - possibly due to the cumulative nature and toxic effects of raised homocysteine .....	24

1.12 Project background and aims .....	24
<i>Chapter 2 Materials and Methods .....</i>	<i>26</i>
2.1 Chemicals and reagents.....	26
2.2 Antibodies .....	26
2.3 Plasmids .....	28
2.4 <i>Mthfr</i> knockout mice.....	28
2.5 P301S-Tau transgenic (TAU58/2) mice.....	28
2.6 Homogenisation of mouse regional brain tissue .....	29
2.7 Plasma and regional brain metabolite analyses.....	29
2.8 Behavioural testing in TAU58/2 mice .....	29
2.9 Acute mouse brain slices.....	31
2.10 Cell culture and transfection .....	31
2.11 Cell treatment.....	32
2.12 Cell lysis and fractionation.....	32
2.13 Immunoprecipitation .....	32
2.14 Western blotting.....	33
2.15 Cell immunofluorescence.....	33
2.16 Statistical analyses .....	34
<i>Chapter 3. Further establishing the critical link between alterations in one-carbon metabolism and AD .....</i>	<i>35</i>
3.1 Introduction.....	35
3.2 MTHFR deficiencies alter Tau phosphorylation at the PHF-1 epitope and Thr668 phosphorylation and protein expression of APP in young <i>Mthfr</i> knockout mice.....	37
3.3 Changes in dietary folate intake and mild MTHFR deficiency in aged mice alter APP Thr668 phosphorylation and protein expression, as well as Tau phosphorylation at the PHF-1 epitope.....	39
3.4 Enhanced APP and Tau phosphorylation in MTHFR and folate deficient mice are associated with enhanced PP2A demethylation and GSK-3 $\beta$ activation. ....	42
3.5 Discussion .....	43

*Chapter 4. Disturbances to one-carbon metabolism and PP2A methylation critically affect Fyn distribution and function..... 50*

4.1 Introduction .....	50
4.2 One-carbon metabolism regulates Fyn cellular distribution and Fyn-dependent neurite outgrowth in N2a cells .....	51
4.3 Methylated PP2A enzymes co-immunoprecipitate with Fyn.....	53
4.4 PP2A methylation regulates Fyn distribution and Fyn-dependent neurite outgrowth in N2a cells.....	54
4.5 PP2A methylation concomitantly regulates F-actin organisation and Fyn compartmentalisation in N2a cells .....	56
4.6 Elevated levels of homocysteine or homocysteine thiolactone induce a redistribution of Fyn and PP2A in acute mouse cortical slices.....	58
4.7 Fyn expression and/or activity is altered in brain regions from MTHFR knockout mice .....	59
4.8 Discussion .....	60

*Chapter 5. Identification of a Fyn-PP2A signalling module ..... 64*

5.1 Introduction .....	64
5.2 Fyn phosphorylates PP2Ac on tyrosine residues in N2a cells .....	65
5.3 Identification of PP2Ac phospho-acceptor sites targeted by Fyn .....	66
5.4 PP2Ac F/F double mutant impedes Fyn <sup>CA</sup> -mediated Tau phosphorylation at AD-like sites and ERK activation.....	67
5.5 Confirmation of Fyn-mediated PP2Ac phosphorylation at “Y2” site, using a validated antibody.....	69
5.6 Fyn <sup>CA</sup> and Y2-phosphorylated PP2Ac co-localise .....	70
5.7 Fyn distribution and function in neurite outgrowth is severely hindered by PP2Ac F/F .....	72
5.8 Discussion .....	73

*Chapter 6. Can we revert AD-like pathology with a diet enriched in methyl group donors? 76*

6.1 Introduction .....	76
6.2 Our methyl group donor-enriched diet reverses motor deficits and improves spatial memory in TAU58/2 mice. ....	77
6.3 Our methyl group donor-enriched diet reduces PP2A demethylation in TAU58/2 mice. ....	79
6.4 Our methyl group donor-enriched diet reduces p-Tau levels in TAU58/2 mice. ....	81

6.5 Our methyl group donor-enriched diet has no effect on APP total protein expression or phosphorylation at Thr668. ....	82
6.6 Our methyl group donor-enriched diet reduces Fyn protein expression levels in the cortex and hippocampus of TAU58/2 mice. ....	83
6.7 Our methyl group donor-enriched diet has no effect on ERK1/2 or GSK-3 $\beta$ activity in TAU58/2 mice .....	85
6.8 Discussion .....	86
<i>Chapter 7 General Discussion</i> .....	90
7.1 Thesis overview .....	90
7.2 Significance.....	93
7.3 Future directions.....	95
7.4 Concluding remarks .....	97
<i>References</i> .....	98
<i>Appendix</i> .....	114

## LIST OF FIGURES

Figure 1. Major neuropathological lesions in AD-affected brain regions.	3
Figure 2. Functionally distinct APP proteolytic cleavage in the brain.	5
Figure 3. Regulation of Tau phosphorylation supports neuronal function and health.	8
Figure 4. Mapping of Tau residues dephosphorylated by and interacting domains of PP2A/B $\alpha$ .	9
Figure 5. Regulation and targeting of Fyn to the plasma membrane.	12
Figure 6. The A $\beta$ -Fyn-Tau signalling cascade: a prominent disease model.	15
Figure 7. Methylation-dependent PP2A/B $\alpha$ holoenzyme biogenesis.	18
Figure 8. Overview of one-carbon metabolism.	20
Figure 9. Overview of studies using mouse models of MTHFR and/or folate deficiencies.	36
Figure 10. Brain region-specific effects of mild and severe MTHFR deficiencies on APP phosphorylation at Thr668 and protein expression levels, and Tau phosphorylation at the PHF-1 epitope in young <i>Mthfr</i> knockout mice.	38
Figure 11. Regional brain cystathionine levels in aged WT and HET mice fed a normal (NF) or low folate (LF) diet.	40
Figure 12. Dietary folate and mild MTHFR deficiencies alter total and Thr668-phosphorylated APP levels and Tau phosphorylation at the PHF-1 epitope in aged mice.	41
Figure 13. MTHFR and folate deficiencies decrease PP2Ac methylation and increase GSK-3 $\beta$ activity.	43
Figure 14. Proposed mechanisms linking dietary folate deficiency and the <i>Mthfr</i> C667T polymorphism to AD.	49
Figure 15. Fyn distribution and Fyn-dependent process outgrowth are dependent on one-carbon metabolism in N2a cells.	52
Figure 16. Methylated PP2A enzymes and Fyn co-immunoprecipitate.	54
Figure 17. Changes in PP2A methylation influence the membrane distribution of Fyn in N2a cells.	55
Figure 18. PP2A methylation state affects Fyn-dependent process initiation and outgrowth.	56
Figure 19. Altering PP2A methylation induces defects in Fyn localisation in N2a cells.	57
Figure 20. Elevated levels of homocysteine affect the presence of methylated PP2A and Fyn enzymes in detergent-insoluble fractions prepared from acute mouse brain slices.	58

Figure 21. Brain region-specific effects of mild and severe MTHFR deficiencies on Fyn expression and/or activity in young <i>Mthfr</i> knockout mice.	60
Figure 22. HA <sub>3</sub> -tagged PP2Ac undergoes tyrosine phosphorylation in N2a cells expressing either Src <sup>CA</sup> or Fyn <sup>CA</sup> , and treated with pervanadate.	66
Figure 23. Identification of HA <sub>3</sub> -tagged PP2Ac phospho-mutants that can block phosphorylation of PP2Ac by Fyn.	67
Figure 24. The PP2Ac F/F mutant inhibits Fyn <sup>CA</sup> -mediated Tau phosphorylation and ERK activation.	68
Figure 25. Fyn <sup>CA</sup> and pervanadate mediate PP2Ac phosphorylation at the Y2 site.	70
Figure 26. Y2 phosphorylated-PP2Ac co-localises with Fyn <sup>CA</sup> in SYF cells.	71
Figure 27. PP2Ac F/F affects Fyn compartmentalisation and function in neurite outgrowth.	72
Figure 28. Methyl group donor supplement intervention in TAU58/2 mice.	77
Figure 29. Our methyl group donor-enriched diet reverses motor deficits and improves spatial learning in TAU58/2 mice.	79
Figure 30. Our methyl group donor-enriched diet reduces demethylated PP2Ac levels in various brain regions in TAU58/2 mice.	80
Figure 31. Our methyl group donor-enriched diet reduces brain p-Tau levels in TAU58/2 mice.	82
Figure 32. APP total protein expression and Thr668-phosphorylation are not affected in TAU58/2 mice fed our methyl group donor-enriched diet.	83
Figure 33. Our methyl group donor-enriched diet reduces cortical and hippocampal Fyn protein expression in TAU58/2 mice.	84
Figure 34. Our methyl group donor-enriched diet has no effect on brain GSK-3 $\beta$ or ERK1/2 activity in TAU58/2 mice.	86
Figure 35. Proposed model for the role of intact one-carbon metabolism and PP2A methylation, and the functional ramifications of their deregulation for Fyn signalling.	92

## LIST OF TABLES

Table 1. Antibodies.	26
Table 2. Plasma tHcy and 5-MTHF levels in young and aged WT, HET and NULL mice fed a normal folate (NF) or low folate (LF) diet.	37

## LIST OF ABBREVIATIONS

AD	Alzheimer's Disease
APP	Amyloid Precursor Protein
A $\beta$	Amyloid beta
CNS	Central nervous system
CP13	Antibody against Tau phosphorylated at Ser202
FTLD-Tau	Frontotemporal Lobar Degeneration-Tau
Fyn <sup>CA</sup>	Constitutively active Fyn
GAPDH	Glyceraldehyde-3-phosphate-dehydrogenase
HET	<i>Mthfr</i> heterozygous knockout genotype
Hcy	Homocysteine
HTL	Homocysteine thiolactone
MCI	Mild cognitive impairment
<i>Mthfr</i>	Gene encoding methylenetetrahydrofolate reductase
MTHFR	Methylenetetrahydrofolate reductase
NFT	Neurofibrillary tangle
NULL	<i>Mthfr</i> homozygous knockout genotype
P-Tau	Hyperphosphorylated Tau
PHF-1	Antibody against Tau phosphorylated at Ser396 and Ser404
PP2A	Protein phosphatase 2A
PP2A/B $\alpha$	Protein phosphatase 2A holoenzyme containing B $\alpha$ subunit
SAM	S-adenosylmethionine
SAH	S-adenosylhomocysteine
SFK	Src family kinase
TAU58/2	Transgenic mice overexpressing human Tau-P301S
THcy	Total homocysteine (homocysteine and derivatives)
WT	Wild-type



## ABSTRACT

Sporadic Alzheimer's Disease (AD) is the prevailing form of dementia worldwide. Neuropathologically, this debilitating disorder is characterised by deposition of senile amyloid beta (A $\beta$ ) plaques and Tau-containing neurofibrillary tangles (NFTs). A $\beta$  peptides are produced from the proteolytic processing of amyloid precursor protein (APP). There is strong experimental evidence that pathological accumulation of A $\beta$  oligomers triggers a degenerative cascade mediated by Fyn kinase and abnormally phosphorylated Tau (p-Tau) proteins; this ultimately promotes synaptic and memory deficits in AD. The deregulation of Tau also prompts its self-aggregation into paired helical filaments that can aggregate further into NFTs. Significant clinical failures of A $\beta$ -centric therapeutics for AD have recently shifted the industry towards development of Tau-targeting approaches that are currently under clinical investigation. However, the sole targeting of either A $\beta$  or p-Tau may fail to address the underlying disease mechanisms, established risk factors, and complexity of this disorder. In an attempt to disentangle some of these issues, we considered the contribution of prevalent modifiable risk factors associated with AD, more specifically, low plasma folate levels and elevated plasma total homocysteine levels. Folate and homocysteine play a key role in one-carbon metabolism, a series of metabolic pathways that control cellular methylation potential. The integrity of one-carbon metabolism is critical for formation of methylation-dependent Protein Phosphatase 2A (PP2A) enzymes, which are major signalling mediators that become downregulated in AD-affected brain regions. Methylated PP2A holoenzymes are the predominant phosphatases that dephosphorylate p-Tau at many Ser/Thr epitopes. They also dephosphorylate APP phosphorylated at the Thr668 residue, which is linked to enhanced APP amyloidogenic processing. Here, we first demonstrated that both APP phosphorylation at Thr668 and Tau phosphorylation at AD-like epitopes are enhanced in various brain regions from mouse models with disturbances to one-carbon metabolism. These changes were associated with a concomitant reduction in methylated PP2A enzyme levels and increased activity of the Tau/APP kinase, GSK-3 $\beta$ . These findings support the involvement of altered one-carbon metabolism in AD pathogenic processes. Since Fyn kinase regulates both APP and Tau *via* Tyrosine (Tyr) phosphorylation, and becomes aberrantly activated in AD, we also deemed it important to address the impact of one-carbon metabolism and PP2A methylation on Fyn regulation. Our studies show that one-carbon metabolism and/or methylated PP2A enzymes regulate the distinct subcellular distribution of Fyn in neuronal cellular and *ex vivo* models. Fyn compartmentalisation was closely associated with its function in neurite outgrowth. Furthermore, we found that Fyn interacted with methylated PP2A enzymes, which may play a role in its targeting. In mice with altered one-carbon metabolism, the net activity and total protein expression levels of Fyn were dramatically altered in a brain region-specific manner; notably, Fyn was hyperactive in the cortex of these mice. Moreover, under conditions of increased Fyn signalling, we identified site-specific Tyr phosphorylation of PP2A catalytic

subunit (PP2Ac), which could have downstream ramifications for both APP and Tau regulation. Tyr phosphorylation of PP2Ac influenced physiological Fyn targeting and Fyn-dependent neurite outgrowth in N2a neuroblastoma cells. Together, our findings support the existence of a reciprocal functional interaction between Fyn and PP2A. Lastly, we demonstrated that a methyl group donor-based intervention ameliorated behavioural impairments, improved spatial memory, and reduced brain p-Tau accumulation in an AD-like mouse model. The mechanisms of action of this intervention likely included Fyn downregulation and the upregulation of methylated PP2A enzymes. Thus, the collective experimental work presented in this thesis unveils novel regulatory mechanisms of significance to AD pathogenesis. Besides opening up new avenues for AD research, our findings should also guide the development of rational therapeutics for delaying AD onset and/or disease progression.